Frontage Laboratories | 01-Oct-2019
| Technical / White Paper
Over the years, the pharmaceutical industry has made steady progress in improving the safety of drugs in development. Consequently, in 2015, only 14 percent...
Frontage Laboratories | 21-Aug-2019
| Technical / White Paper
Immunogenicity is the leading reason that biologics fail in clinical trials, and thus it has become imperative for drug development programs to include...
The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...
BBK Worldwide | 24-Jul-2019
| Technical / White Paper
Despite growing evidence, the myth that physicians won’t refer patients to clinical trials persists, perpetuated by the belief that they fear losing their...
